Future of Digital Medicine and Clinical Trials with Novel Machine Learning and AI Architectures
Phase 3 clinical outcome trials to evaluate new drugs, therapies, and vaccines are the most complex experiments performed in medicine. Around 50% of phase 3 trials fail, costing healthcare industries, governments, and academic research hospitals billions of dollars and delay life-saving treatments to patients. This talk will share novel phase 2 and 3 clinical trials designed by unorthodox “self-learning” AI algorithms to help accelerate medical product development and bring new innovations and advances to patients safely. Our clinical trial design achieves significant reduction in tumor sizes in patients suffering from glioblastomas (brain tumors) and offers personalized and precision dosing recommendations to individuals compared to human-expert policies. We outline a strategic plan to conduct clinical trials with devices, algorithms, and real-world evidence in accordance with the 21st Century Cures Act.